Molecular cancer therapy

Moktan, S., Perkins, E., Kratz, F., Rancher, D. (2012). Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the Parent compound in vivo. Molecular Cancer Therapy, 11(1), 1547-1556. 

Kawata, E., et al.. Administration of PLK-1 small interfering RNA with atelocoUagen prevents the growth of fiver metastases of lung cancer. Molecular Cancer Therapy, 7 2904-2912, 2008. 

Modem cancer therapy has been primarily dependent upon surgery, radiotherapy, chemotherapy, and hormonal therapy (72) (see Chemotherapeutics,anticancer Hormones Radiopharmaceuticals). Chemotherapeutic agents maybe able to retard the rate of growth, but are unable to eradicate the entire population of neoplastic cells without significant destmction of normal host tissue. This serious side effect limits general use. More recentiy, the immunotherapeutic approach to cancer has involved modification and exploitation of the cellular and molecular mechanisms in host defense, regulation of tissue proliferation, tissue differentiation, and tissue survival. The results have been more than encouraging. 

CNTs have been studied for cancer therapies despite the fact that these have been shown to accumulate to toxic levels within the organs of diverse animal models and different cell lines (Fiorito et al., 2006 Tong and Cheng, 2007). The molecular and cellular mechanisms for toxicity of carbon nanotubes have not been fully clarified. Furthermore, toxicity must be examined on the basis of multiple routes of administration (i.e., pulmonary, transdermal, ocular, oral, and intravenous) and on multiple species mammals, lower terrestrial animals, aquatic animals (both vertebrates and invertebrates), and plants (both terrestrial and aquatic). A basic set of tests for risk assessment of nanomaterials has been put forward (Nano risk framework). 

Insights at the molecular level will lead to better cancer therapy... 

Wallace EM, LyssikatosJ, Blake JF, Seo J, YangHW, Yeh TC, Perrier M, Jarski H, Marsh V, Poch G, Goyette Livingston M, Otten J, Hingorani G, Woessner R, Win-ski SL, Anderson DA, Lee P, Winkler J, Koch K (2005) Abstracts of the AACR-NCl-EORTC International Conference on Molecular Targets and Cancer Therapy, Philadelphia, 14-18 Nov 2005 Abstr B77... 

---